News

25 Aug 2026

Solvonis Raises £1.3 Million

25 Aug 2026

Solvonis Raises £1.3 Million

25 Aug 2026

Solvonis Raises £1.3 Million

6 Aug 2026

SVN-015 Advances in NIDA-Funded Studies Following Encouraging Initial Screening

6 Aug 2026

SVN-015 Advances in NIDA-Funded Studies Following Encouraging Initial Screening

6 Aug 2026

SVN-015 Advances in NIDA-Funded Studies Following Encouraging Initial Screening

13 Jul 2026

Water Tower Research Initiates Coverage

13 Jul 2026

Water Tower Research Initiates Coverage

13 Jul 2026

Water Tower Research Initiates Coverage

22 Jun 2026

Solvonis Announces Positive SVN-002 Bridging Data

22 Jun 2026

Solvonis Announces Positive SVN-002 Bridging Data

22 Jun 2026

Solvonis Announces Positive SVN-002 Bridging Data

19 Jun 2026

Solvonis Announces Result of Annual General Meeting

19 Jun 2026

Solvonis Announces Result of Annual General Meeting

19 Jun 2026

Solvonis Announces Result of Annual General Meeting

5 May 2026

CSO Speaks at US National Research Meeting

5 May 2026

CSO Speaks at US National Research Meeting

5 May 2026

CSO Speaks at US National Research Meeting

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

Load More